Gene · 9589
Papers3,474
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,474
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| m6A modification and its clinical applications in gynaecological cancer. | Apoptosis | 2026 | 41518553 | PubTator, text mining | PubMed |
| Cotranslational assembly directs the biogenesis of the m6A methyltransferase complex. | Proc Natl Acad Sci U S A | 2026 | 41481436 | PubTator, text mining | PubMed |
| WTAP contributes to the malignancy and stemness of hepatocellular carcinoma through upregulating N6-methyladenosine modification of ITGB4. | Pathol Res Pract | 2026 | 41456451 | PubTator, text mining | PubMed |
| Epitranscriptomic modifications in embryonic development: insights into natural and ART-induced mechanisms and implications. | Hum Reprod Update | 2026 | 41445111 | PubTator, text mining | PubMed |
| The progress of m6A methylation-regulated non-coding RNAs in osteogenic differentiation and osteoporosis. | Noncoding RNA Res | 2026 | 41439031 | PubTator, text mining | PubMed |
| Correction: Activated MAFB in ovarian cancer promotes cytoskeletal remodeling and immune microenvironment suppression by interfering with m6A modifications through WTAP competition. | Oncogene | 2026 | 41350925 | PubTator, text mining | PubMed |
| Bioinformatics and In Vitro/In Vivo Experiments Identify MAD2L1 as an m6A-Associated Biomarker Promoting Oral Squamous Cell Carcinoma Progression. | J Oral Pathol Med | 2026 | 41320992 | PubTator, text mining | PubMed |
| N6-methyladenosine (m6A) modification regulates LONP1 to inhibit coxsackievirus B3 replication by suppressing virus-induced ferroptosis. | Int J Biol Macromol | 2026 | 41317762 | PubTator, text mining | PubMed |
| Per- and polyfluoroalkyl substances induce cytotoxicity in NCI-H446 cells through modulating proliferation, apoptosis, and m6A methylation. | Food Chem Toxicol | 2026 | 41314428 | PubTator, text mining | PubMed |
| EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway. | J Clin Invest | 2026 | 41252201 | PubTator, text mining | PubMed |
| WTAP-mediated m6A modification of PRMT1 regulates cuproptosis to promote anaplastic thyroid carcinoma progression. | Tissue Cell | 2026 | 41240789 | PubTator, text mining | PubMed |
| WTAP promotes the proliferation of multiple myeloma by regulating the hippo pathway through m6A modification of MAP6D1. | Leuk Lymphoma | 2026 | 41200937 | PubTator, text mining | PubMed |
| Mechanism of Tumour-Associated Macrophage-Derived Exosomes in Chemo-Sensitivity of Laryngeal Cancer by Regulating Aerobic Glycolysis via WTAP/GLUT-1. | Immunology | 2026 | 41038674 | PubTator, text mining | PubMed |
| Astragalosides Promote MH7A Cell Apoptosis by Suppressing WTAP-mediated m6A Methylation of TRAIL-DR4. | Comb Chem High Throughput Screen | 2026 | 40143691 | PubTator, text mining | PubMed |
| CD133-Guided RNA Nanoparticle Delivery of FTO siRNA Impairs Leukemia Resistance to Tyrosine Kinase Inhibitor Therapy. | RNA Nanomed | 2025 | 42004278 | PubTator, text mining | PubMed |
| Harnessing m6A-regulated cholesterol biosynthesis helps impede tumor burden and stemness in high-garde serous ovarian carcinoma mesenchymal phenotype. | Mol Med | 2025 | 41466215 | PubTator, text mining | PubMed |
| IGF2BP3-STAT3-METTL3 axis promotes malignant progression in hepatocellular carcinoma (HCC). | Hum Genomics | 2025 | 41449478 | PubTator, text mining | PubMed |
| Xist in X chromosome inactivation: mechanisms and disease relevance. | Cell Commun Signal | 2025 | 41430272 | PubTator, text mining | PubMed |
Analysis of the clinical value of combined monitoring of methylation transferase Wilms' tumour 1-associating protein and lipoprotein-associated phospholipase A2 in patients with coronary artery disease. | Front Cardiovasc Med | 2025 | 41425989 | PubTator, text mining | PubMed |
| PXDN regulated by WTAP/YTHDF1-mediated m6A modification activates PI3K/AKT signaling pathway through extracellular matrix remodeling to promote progression in nasopharyngeal carcinoma. | J Exp Clin Cancer Res | 2025 | 41413560 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9589/papers?page=6